CA-CROWN-BIOSCIENCE
Crown Bioscience, a leading global contract research organization (CRO) and a JSR Life Sciences company, today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
The company’s Hamburg facility, Indivumed Services, received CAP 15189 Accreditation; ISO 15189:2012 standard for biospecimen tissue management practices, building on the facility’s pre-existing CAP accreditation, which was awarded in June 2023. To complement this, Crown Bioscience’s Suzhou site has recently been awarded CAP accreditation for biomarker laboratory services, covering areas such as surgical pathology, tissue processing, and complex solid tumor molecular sequencing. These recognitions affirm the consistent elevation in the quality and precision of Crown Bioscience's laboratory practices, placing the company among a select number of laboratories meeting the stringent CAP and ISO quality standards within preclinical and translational cancer research.
Assessors commended Crown Bioscience for its quality-centric culture and the proficiency of its technicians, who are deeply knowledgeable about quality standards and specialized prerequisites for client studies. This environment of trust and precision is bolstered by the company’s ISO certification portfolio, which includes over a decade of ISO 9001 standards in quality and risk management.
Pam Shang, EMBA, Vice President of Global Quality and Regulatory Compliance, said: "The pace at which we progressed from initial gap assessment to CAP Accreditations was unparalleled, highlighting our robust quality management framework and technical proficiency. This further demonstrates our goal to uphold the highest standards of quality management systems and customer satisfaction."
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 13 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411630297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MBK Partners: Welcoming the Court’s Decision to Prohibit Cumulative Voting for Director Appointments21.1.2025 12:31:00 CET | Press release
Korea Zinc’s Extraordinary General Meeting to Be Conducted Fairly Using a Simple Voting Method MBK Partners and Young Poong, the largest shareholders of Korea Zinc, issue the following statement regarding today’s decision by the Seoul Central District Court’s Civil Division 50 to grant an injunction prohibiting the use of cumulative voting for director appointments at Korea Zinc: MBK Partners and Young Poong welcome the court’s decision to prohibit cumulative voting and view this outcome as a natural and lawful conclusion. The cumulative voting request filed by Yumi Development, for the sole purpose of securing Chairman Yoon Bum Choi’s position, failed to meet the procedural requirements outlined in Article 382-2 of the Korean Commercial Act. The court ruled that while Yumi Development submitted the cumulative voting request on December 10, Korea Zinc’s Articles of Incorporation at that time explicitly stated, “the cumulative voting system shall not apply.” As such, the request violate
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer21.1.2025 12:30:00 CET | Press release
Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by the company are focused on addressing unmet needs in current clinical care and are designed to improve patient outcomes. “Steve has spent the past four years working to deeply understand barriers to care for patients living with serious mental health conditions and he is committed to helping find solutions to address those barriers,” said Kabir Nath, CEO of Compass Pathways. “Steve shares
Epsilon Carbon Launches Terrablack, a High-Performing and Environment Friendly Recovered Carbon Black for the Tire and Non-Tire Industries21.1.2025 09:44:00 CET | Press release
Epsilon Carbon, a global leader in the carbon black industry, announces the launch of Terrablack, a product line that aims to shape the carbon black sector with sustainability at its core. The unveiling took place in the presence of Mr. Sajjan Jindal, Chairman and MD – JSW Group, Mr. Vikram Handa, Managing Director - Epsilon Carbon, Mr. Gaurav Mathur, CEO and Mr. Desh Deepak Misra, President - Carbon Black business at the Bharat Mobility Show’s India International Tire Exhibition, New Delhi. Terrablack is designed to address the growing demand for sustainable carbon black. Using recovered carbon black (rCB) and Tire-derived oil (TDO), this product line is formulated after 24 months of in-depth testing and collaboration to shape the future of carbon black production. It offers high-performance, eco-friendly solutions that meet the needs of both Tire and non-Tire industries. The Terrablack portfolio includes Terrablack 3310, engineered for heavy-duty applications like Tire treads, offeri
Hydrogen equipment pioneer H2SITE successfully raises EUR36 million from a consortium of investors co-led by Hy24 and SC Net Zero Ventures21.1.2025 08:42:00 CET | Press release
The Series B Funding round is co-led by Hy24 and SC Net Zero Ventures who are joined by Breakthrough Energy Ventures, Enagas Emprende, Equinor Ventures, Exergon, Ezten, and MassMutal Ventures. The investment round will support the next phases of H2SITE’s innovative hydrogen technology deployment, focusing on scaling up to multi tons per day reactors in operation by 2026. H2SITE’s solution addresses the challenges of transporting hydrogen, making the technology more accessible and creating significant cost savings. H2SITE, a deep-tech pioneer of hydrogen separation solutions, announces today the successful closing of its Series B funding round at EUR36 million from a consortium of investors, combining strategic and financial investors focused on the next growth phase. H2SITE has received support from new co-lead investors Hy24, the world’s leading low-carbon hydrogen pure-play investment manager, through its Clean Hydrogen Equipment Fund, and SC Net Zero Ventures, the climate tech ventu
Bureau Veritas to Acquire a Leading Buildings & Infrastructure Business in Italy in Line With LEAP I 2820.1.2025 19:03:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services, announced that it has signed an agreement to acquire Contec AQS and its two owned subsidiaries Exenet and PMPI. The planned acquisition is aligned with Bureau Veritas’ LEAP | 28 strategy to expand its leadership in the Buildings and Infrastructure market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250120728164/en/ Hinda Gharbi, CEO Bureau Veritas (Photo: Business Wire) Bureau Veritas contributes to safer, sustainable, and resilient buildings and infrastructure, delivering comprehensive solutions covering the full life cycle of assets. This acquisition will expand Bureau Veritas’ Buildings and Infrastructure footprint in Italy. Contec AQS, Exenet and PMPI are established Italian brands delivering comprehensive services and technical expertise in the Buildings and Infrastructure sector. They cover construction, infrastructure and Health, Sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom